UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
September 6, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors
of
Hepatitis C at an Upcoming International Scientific
Conference
Oral
presentation will be held on September 13, 2007 at the 14th International
Symposium on Hepatitis C Virus & Related Viruses to be held in Glasgow,
Scotland
Valley
Cottage, New York, September 6, 2007
- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced today
that
a late breaker abstract, entitled “Potent Small Molecule HCV Inhibitors
Affecting NS5A-dependent Functions,” was selected for oral presentation at the
14th International Symposium on Hepatitis C Virus & Related Viruses
(www.hcv2007.com).
The
presentation will take place at 10:30 Greenwich Mean time on Thursday, September
13, 2007, and a press release outlining the data presented will be released
by
the Company shortly thereafter.
The
compounds that will be presented at the conference emerged from the Company’s
DOS program, aimed at discovering novel hepatitis C inhibitors applying a
unique
chemistry technology called Diversity Oriented Synthesis. The DOS program
was
acquired by the Company in late 2005.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of neuropathic pain and hepatitis C. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active in-licensing
and acquisition program designed to identify and acquire additional drug
candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: September 6, 2007 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
| Chief Executive Officer | ||